BioVersys Future Growth
Future criteria checks 2/6
BioVersys is forecast to grow earnings and revenue by 38.9% and 50.4% per annum respectively. EPS is expected to grow by 36.7% per annum. Return on equity is forecast to be -504% in 3 years.
Key information
38.9%
Earnings growth rate
36.69%
EPS growth rate
| Pharmaceuticals earnings growth | 12.0% |
| Revenue growth rate | 50.4% |
| Future return on equity | -503.99% |
| Analyst coverage | Good |
| Last updated | 11 Sep 2026 |
Recent future growth updates
Recent updates
BIOV: Higher Fair Value Will Support Stronger Long Term Profitability
Analysts have raised their price target for BioVersys from CHF 70 to CHF 100, citing updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E, which together support a higher valuation range. What’s in the News for BioVersys No recent news stories for BioVersys were identified in the provided sources as of 3 September 2026.
Antibiotic Subscription Reforms And External Funding Will Support Long Term Anti Infective Upside
Catalysts About BioVersys BioVersys develops antibiotics and anti infective therapies targeting high mortality, drug resistant infections and tuberculosis. What are the underlying business or industry changes driving this perspective?
Antibiotic Trial And Reimbursement Setbacks Will Pressure Results Before Long Term Potential Emerges
Catalysts About BioVersys BioVersys is a biopharmaceutical company focused on developing antibiotics for severe drug resistant infections and tuberculosis. What are the underlying business or industry changes driving this perspective?Global Antibiotic Partnerships And New Reimbursement Models Will Support Strong Future Potential
Catalysts About BioVersys BioVersys is a clinical stage biopharmaceutical company focused on antibiotics targeting severe drug resistant infections and tuberculosis. What are the underlying business or industry changes driving this perspective?Is BioVersys (VTX:BIOV) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2028 | 26 | -29 | -29 | -29 | 3 |
| 12/31/2027 | 5 | -30 | -27 | -24 | 5 |
| 12/31/2026 | 2 | -33 | -31 | -32 | 3 |
| 6/30/2026 | 5 | -26 | -26 | -25 | N/A |
| 3/31/2026 | 4 | -24 | -24 | -24 | N/A |
| 12/31/2025 | 3 | -22 | -22 | -22 | N/A |
| 9/30/2025 | 2 | -21 | -19 | -19 | N/A |
| 6/30/2025 | 1 | -19 | -17 | -17 | N/A |
| 3/31/2025 | 1 | -19 | -16 | -16 | N/A |
| 12/31/2024 | 1 | -19 | -16 | -16 | N/A |
| 12/31/2023 | 1 | -18 | -12 | -12 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BIOV is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BIOV is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BIOV is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BIOV's revenue (50.4% per year) is forecast to grow faster than the Swiss market (5.2% per year).
High Growth Revenue: BIOV's revenue (50.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BIOV is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/14 02:18 |
| End of Day Share Price | 2026/09/14 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioVersys AG is covered by 7 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jelena Milovic | Citigroup Inc |
| Jyoti Prakash | Edison Investment Research |
| Raghuram Selvaraju | H.C. Wainwright & Co. |